Sabrina Prabakaran
Gastroenterology · Tampa, FLNPI 1003340076
Payments from drug & device makers
Across 104 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$794
- Johnson & Johnson$240
- Lilly USA, LLC$172
- Boston Scientific$158
- Madrigal Pharmaceuticals$96
- Celltrion USA Inc.$82
- plus $671 from 15 others
What the payments were for
- Food & beverage$2,18899%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $794 |
| Johnson & Johnson | 16 | $240 |
| Lilly USA, LLC | 7 | $172 |
| Boston Scientific | 3 | $158 |
| Madrigal Pharmaceuticals | 5 | $96 |
| Celltrion USA Inc. | 3 | $82 |
| Phathom Pharmaceuticals, Inc. | 4 | $78 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| Mallinckrodt Hospital Products Inc. | 2 | $71 |
| Aimmune Therapeutics, Inc. | 3 | $65 |
| Medtronic | 2 | $60 |
| Sanofi | 2 | $57 |
| Exact Sciences | 2 | $48 |
| Bristol Myers Squibb | 3 | $45 |
| Vivus LLC | 2 | $35 |
| Novo Nordisk | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Braintree Laboratories, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
How this compares
$2,212 in reported general payments places this provider in the 35th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colestipol Hcl | 13 | $1,055 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Tampa
- Alan WeintraubTampa$4.7M
- Angel RosarioTampa$1.4M
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.